Bryan Johnson

Background

Bryan Johnson founded Braintree (acquired by PayPal for Venmo) and Kernel (neurotech). Since 2021 his public focus has been Project Blueprint, a heavily-instrumented attempt to maximise biomarkers of aging across multiple metrics, with a stated goal of "Don’t Die."

Approach

• Very-low-calorie nutrient-dense diet (~2,250 kcal/day vegan/pescatarian).
• Strict sleep schedule (~early-to-bed).
• Daily exercise protocol.
• ~70+ supplements daily.
• Off-label use of multiple longevity-adjacent drugs (low-dose rapamycin until 2024, then discontinued; metformin; PCSK9 inhibitors; others).
• Quarterly comprehensive biomarker panels published publicly.
• Brief exploration of plasma transfusion from son to father (later discontinued).

Why it’s in this reference

Johnson is the most-visible example of n=1 self-experimentation in longevity-curious public. Two views are reasonable:

• Productive: he publishes his protocol and data, which helps the field debate what actually works.
• Cautionary: many of his interventions have weak evidence; cost is enormous and rotates with his evolving views; survivorship bias of his cohort-of-one is severe.

Reading Blueprint

The published protocols are useful for seeing what a maximalist longevity-tracking stack looks like. They should not be confused with evidence-based recommendations for the general population.

Related entries

Rapamycin, Function Health, Concept: pace of aging, Biological vs chronological age.